Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase 2 4Phase 2/3 2Phase 1/2 2Phase 1 2Phase 3 1

Status

Recruiting 1Not yet recruiting 1Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Hepatocellular 59Cholangiocarcinoma 19Carcinoma, Renal Cell 16Biliary Tract Neoplasms 11Stomach Neoplasms 9Thyroid Neoplasms 8Endometrial Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Neoplasms 7Melanoma 6Uterine Cervical Neoplasms 5Thyroid Carcinoma, Anaplastic 5Neuroendocrine Tumors 5Carcinoma, Non-Small-Cell Lung 5Recurrence 4Ovarian Neoplasms 4Liver Neoplasms 4Thyroid Cancer, Papillary 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Neoplasm Metastasis 3Cirrhosis, Familial, with Pulmonary Hypertension 3Brain Neoplasms 3Advanced Biliary Tract Cancer 3Adenocarcinoma, Follicular 3Vulvar Neoplasms 2Uveal Melanoma 2Triple Negative Breast Neoplasms 2Thymoma 2Solid Tumors 2

Interventions

Bevacizumab 23Sorafenib 20Doxorubicin 14Gemcitabine 11durvalumab 10Oxaliplatin 10Fluorouracil 10Cisplatin 10Capecitabine 9Nivolumab 8pembrolizumab 6Sunitinib 6tremelimumab 5atezolizumab 5Radiofrequency Ablation 5Neoadjuvant Therapy 5Leucovorin 5lenvatinib 4aldesleukin 4Thalidomide 4Radiotherapy 4Radiosurgery 4Everolimus 4Erlotinib Hydrochloride 4Drug Therapy 4Carboplatin 4toripalimab 3regorafenib 3camrelizumab 3apatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Liver Neoplasms × lenvatinib × Clear all
NCT05532319 2025-12-30

FRONT-1

Guangxi Medical University

Phase 2 Completed
64 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05185739 2024-12-06

PRIMER-1

University College, London

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06563934 2024-08-21

Gut Microbiota in Liver Cancer (Treated With TKIs In Combination With ICIs)

Shenzhen Third People's Hospital

Phase 2 Not yet recruiting
70 enrolled
Gastrointestinal

Liver Neoplasms

NCT05171335 2022-09-21

Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients

The Methodist Hospital Research Institute

Phase 2 Enrolling by invitation
50 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡